Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction  by Voisine, Pierre et al.
Cardiopulmonary Support and Physiology Voisine et al
CSPNormalization of coronary microvascular reactivity and
improvement in myocardial perfusion by surgical vascular
endothelial growth factor therapy combined with oral
supplementation of L-arginine in a porcine model of
endothelial dysfunction
Pierre Voisine, MD,a Cesario Bianchi, MD, PhD,a Tanveer A. Khan, MD,a Marc Ruel, MD, MPH,a Shu-Hua Xu, PhD,aJun Feng, MD, PhD,a Jian Li, MD, PhD,b Tamer Malik, MD,a Audrey Rosinberg, MD,a and Frank W. Sellke, MDaFrom the Divisions of Cardiothoracic Sur-
gerya and Cardiology,b Beth Israel Deacon-
ess Medical Center, Boston, Mass.
Supported by grant R01 HL69024 from the
National Institutes of Health (Dr Sellke). Dr
Voisine is a research fellow of the Heart
and Stroke Foundation of Canada.
Read at the Eighty-fourth Annual Meeting
of The American Association for Thoracic
Surgery, Toronto, Ontario, Canada, April
25-28, 2004.
Received for publication April 24, 2004;
revisions received Nov 15, 2004; accepted
for publication Dec 7, 2004.
Address for reprints: Pierre Voisine, MD, Di-
vision of Cardiothoracic Surgery, Beth Israel
Deaconess Medical Center, 330 Brookline
Ave, DANA 881, Boston, MA 02215
(E-mail: pvoisine@bidmc.harvard.edu).
J Thorac Cardiovasc Surg 2005;129:1414-20
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.12.046
1414 The Journal of Thoracic and CardObjective: Vascular endothelial growth factor acts in part through nitric oxide
release, the availability of which is decreased in endothelial dysfunction associated
with advanced coronary artery disease. This could explain the relatively disappoint-
ing results of vascular endothelial growth factor therapy in clinical studies compared
with animal studies. We examined the influence of L-arginine supplementation to
vascular endothelial growth factor therapy on myocardial microvascular reactivity
and perfusion in a porcine model of endothelial dysfunction.
Methods: Twenty-four pigs were fed either a normal (NORM, n  8) or high-
cholesterol diet with (CHOL-ARG, n 8) or without (CHOL, n 8) L-arginine. All
pigs underwent ameroid placement on the circumflex artery and then 3 weeks later
received surgical vascular endothelial growth factor treatment. Four weeks after
treatment, endothelial-dependent coronary microvascular responses and lateral
myocardial perfusion were assessed. Endothelial cell density was determined by
means of immunohistochemistry. Vascular endothelial growth factor, endothelial
nitric oxide synthase, and Akt levels were determined by means of immunoblotting.
Results: Pigs from the CHOL group showed endothelial dysfunction in the circum-
flex territory, which was normalized by L-arginine supplementation. Vascular en-
dothelial growth factor treatment was ineffective in the CHOL group (circumflex/
left anterior descending coronary artery blood flow ratios: 0.95 [rest] and 0.74 [pace]
before-after treatment; P  .05 compared with the NORM group). Addition of
L-arginine restored the angiogenic effect of vascular endothelial growth factor
(ratios: 1.13 [rest] and 1.20 [pace]; P  .05) and was associated with increased
endothelial cell density, as well as vascular endothelial growth factor, endothelial
nitric oxide synthase, and Akt protein levels in the ischemic territory.
Conclusions: L-Arginine supplementation can restore normal endothelium-dependent
vasorelaxation and angiogenic response to vascular endothelial growth factor in a swine
model of chronic myocardial ischemia with hypercholesterolemia-induced endothelial
dysfunction. These findings suggest a putative role for L-arginine in combination with
vascular endothelial growth factor therapy for end-stage coronary artery disease.
Growth factor–based therapeutic angiogenesis is an attractive alternative strategyfor patients with advanced coronary artery disease (CAD) who are not suitablecandidates for conventional revascularization techniques. Despite some encour-
aging results in clinical trials testing the efficacy of vascular endothelial growth factor
(VEGF) and fibroblast growth factor (FGF) 2, the use of growth factors in human
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Psubjects has not fulfilled the enthusiastic expectations that
successful studies in several animal models of ischemia have
generated.1,2
The reasons for the discrepancies between the results
from animal and human studies are unclear. However,
VEGF and other angiogenic growth factors operate in large
part through the release of endothelial-derived nitric oxide
(NO) through the activation of tyrosine kinase receptors.3
Because patients with CAD typically display several risk
factors for endothelial dysfunction, the lack of growth
factor–mediated angiogenic effects in this population might
be related to a deficiency in the stimulated release of NO as
a result of their disease state.4 There is in vitro evidence that
an important relationship exists between the release of NO
and the regulation of VEGF-mediated blood vessel growth
and development. VEGF enhances the expression of endothe-
lial nitric oxide synthase (eNOS) in native and cultured endo-
thelial cells, an effect that might be important in the process of
VEGF-induced angiogenesis,5 and eNOS expression is in-
creased in proliferating compared with confluent endothelial
cells.6 Moreover, inhibitors of NOS suppress angiogenesis,
and the proliferative effect of VEGF is decreased in the pres-
ence of NOS inhibitors.7,8 A recent study also shows in vivo
inhibition of VEGF-mediated myocardial angiogenesis in a
porcine model of hypercholesterolemia-induced endothelial
dysfunction.9
Meanwhile, a considerable number of animal and human
studies suggest a beneficial role of L-arginine, the substrate
for eNOS, on endothelial function. L-Arginine has been
shown to prevent intimal thickening in the coronary arteries
of hypercholesterolemic rabbits independently of alterations
in plasma cholesterol levels.10 L-Arginine administration in
human subjects has been associated with improved epicar-
dial and microvascular responses to acetylcholine in pa-
tients with endothelial dysfunction.11 In a double-blind,
randomized study investigating the effects of chronic di-
etary supplementation with L-arginine in human subjects
with nonobstructive CAD, an increase in coronary blood
flow in response to acetylcholine (associated with a de-
crease in plasma endothelin concentrations and an improve-
ment in patients’ symptoms) was observed.12
Accordingly, we examined the effects of chronic oral ad-
ministration of L-arginine on the impaired angiogenic response




Twenty-four Yucatan miniswine (Sinclair Research, Columbia,
Mo) were either fed a regular chow (NORM, n  8) or a hyper-
cholesterolemic diet (n  16) with (HICHOL-ARG, n  8) or
without (HICHOL, n  8) oral supplementation of L-arginine (50
mg/kg by mouth twice daily). The high-cholesterol diet (4% cho-
lesterol, 17.2% coconut oil, 2.3% corn oil, 1.5% sodium cholate,
The Journal of Thoracicand 75% regular chow) and L-arginine administration were started
at 7 weeks of age and continued throughout the entire study period
(total period of 20 weeks). All animals received humane care in
compliance with the Harvard Medical Area Institutional Animal
Care and Use Committee and the National Research Council’s
“Guide for the Care and Use of Laboratory Animals” (National
Institutes of Health publication no. 5377-3, revised 1996). The
remaining steps of the protocol have been described elsewhere9
and are briefly outlined below.
An ameroid constrictor (1.75-mm internal diameter) was placed
on the proximal circumflex coronary artery of each pig through a left
minithoracotomy. Red-gold microspheres (BioPhysics Assay Labo-
ratory, Worcester, Mass) were injected in the left atrium during
temporary occlusion of the circumflex artery to determine the exact
myocardial territory at risk (the shadow-labeling procedure).
Three weeks after ameroid insertion, coronary angiograms
were recorded, and a left thoracotomy was performed. Micro-
spheres (1.5  107) were injected both at rest (samarium) and
during pacing at 150 beats/min (lanthanum) for perfusion analysis.
In all pigs VEGF administration was then started with an osmotic
pump system (ALZET, model 2MLA; Alza, Palo Alto, Calif),
delivering a total of 2 g of human recombinant VEGF165 (R&D
Systems, Minneapolis, Minn) at a rate of 3 ng/h within the myo-
cardium adjacent to the circumflex artery.
Four weeks later, coronary arteriography was repeated, hearts
were exposed, and microspheres (lutetium at rest and ytterbium
under pacing) were injected as described above. After death, hearts
were harvested and cut at the midventricular level and then sec-
tioned into systematically identified segments. Samples from the
anterior and left lateral walls were used for molecular studies, in
vitro assessment of microvessel reactivity, and microsphere per-
fusion analyses.
In Vitro Assessment of Coronary Microvessel
Reactivity
After cardiac harvest, epicardial coronary arterioles (70-150
m in diameter and 1-2 mm in length) originating from
branches of the left anterior descending artery (LAD) and left
circumflex artery were dissected and examined in isolated organ
chambers, as described previously.13 The responses to sodium
nitroprusside (SNP; 1 nmol/L to 100 mol/L), an endothelium-
independent cyclic guanosine monophosphate–mediated vaso-
dilator, as well as responses to adenosine 5= diphosphate (ADP;
(1 nmol/L to 10 mol/L) and VEGF (1 fmol/L to 1 nmol/L),
endothelium-dependent receptor-mediated vasodilators that act
through bioavailable NO, were studied.14
Perfusion Analyses
Myocardial blood flows were determined during each procedure
with isotope-labeled microspheres (BioPAL, Worcester, Mass) by
using methods previously reported.9,15 Isotope-labeled micro-
spheres of different isotopic masses were used at each experimen-
tal stage, as explained in the “Study design” section.
Western Blotting
Whole-cell lysates were isolated from the homogenized anterior
and lateral myocardium, and Western Blot analyses were per-
and Cardiovascular Surgery ● Volume 129, Number 6 1415
Cardiopulmonary Support and Physiology Voisine et al
CSPformed as previously described9 with a 1:1000 dilution of poly-
clonal anti-human VEGF antibody (Oncogene, Boston, Mass), a
1:1000 dilution of anti-eNOS antibody (Cell Signaling, Beverly,
Mass), and a 1:1000 dilution of polyclonal anti-rabbit antibody for
Akt (Santa Cruz Biotechnology Inc, Santa Cruz, Calif).
Immunohistochemistry
Staining with CD31 antibody (BD Biosciences Pharmingen, San
Diego, Calif) was done according to methods previously reported.9
Regional Contractility
Regional myocardial function was assessed by means of
sonomicrometry (Sonometrics Digital Ultrasonic Measurement
System; Sonometrics Corp, London, Ontario, Canada) with 2
digital piezoelectric ultrasonic probes (2.0 mm) implanted in
the subendocardial layer approximately 10 mm apart within the
collateral-dependent area parallel to the minor axis of the heart
and by determining the percentage of segmental shortening
during systole.
Data Analysis
Data are reported as means  standard error of the mean. Com-
parisons between groups were analyzed by means of 1-way anal-
ysis of variance with the Bonferroni multiple comparison test,
followed by a 2-tailed t test with Microsoft Excel (Microsoft Corp,
Seattle, Wash) and GraphPad Prism (GraphPad Software Inc, San
Diego, Calif). Microvessel responses are expressed as the percent-
age of relaxation of the preconstricted diameter and were analyzed
by fitting a linear regression model examining the relationship
among vessel relaxation, log concentration of the vasoactive agent
of interest, and the experimental group or myocardial territory of
origin (SAS Version 8, Cary, NC). Immunoblottings were ana-
lyzed as previously described.9
Results
Animal Model
Two pigs from the HICHOL group died before completion
of the experimental protocol. The first one died 24 hours
after ameroid placement, probably from arrhythmia, and the
second pig died at the time of the treatment procedure from
acute heart failure after pacing at 150 beats/min, which
eventually led to ventricular fibrillation that was unrespon-
sive to pharmacologic intervention and defibrillation. There
was one death in the HICHOL-ARG group 3 days after
VEGF treatment caused by acute aortic thrombosis at the
iliac bifurcation level. All pigs from the NORM group
completed the study.
Serum cholesterol levels were not significantly different
in the HICHOL and HICHOL-ARG groups but were sig-
nificantly higher than in the NORM pigs at all time points.
Total serum cholesterol levels for these 3 groups were,
respectively, 9.3  1.6, 10.0  0.9, and 1.1  0.2 mmol/L
at the time of ameroid placement; 10.2 2.1, 9.3 1.0, and
1.0  0.8 mmol/L at the time of VEGF treatment; and 10.4
 1.3, 10.1  1.2, and 1.2  0.2 mmol/L at the time of
harvest (P  .01).
1416 The Journal of Thoracic and Cardiovascular Surgery ● JunL-Arginine levels were not statistically different in the 3
groups (HICHOL, 62.6  9.2 mmol/mL; HICHOL-ARG,
68.3  8.6 mmol/mL; and NORM, 66.8  9.8 mmol/L).
Coronary angiograms confirmed the complete closure of
the ameroid constrictors in all animals, with impaired distal
filling of the circumflex (TIMI 2 flow). There was no
significant difference in the visible collateral vessel devel-
opment among the 3 groups.
Microvessel Reactivity
Figure 1 shows the relaxation curves to increasing concentra-
tions of vasodilators after preconstriction with the thromboxane-
prostaglandin endoperoxide analogue U46619. Endothelial
dysfunction in the high-cholesterol-diet group was evidenced
by the significantly impaired vasorelaxation to ADP and
VEGF, 2 endothelium-dependent vasodilators, in the circum-
flex distribution (P .001 and P .006 vs the LAD territory,
respectively; Figure 1, B). Relaxation to the endothelium-
independent agent SNP also showed a decreased response in
the ischemic area (P  .03; Figure 1, B). Contrastingly, there
was no difference in the curve responses from the circumflex
and LAD territories in the normal diet group (Figure 1, A), and
all the altered microvascular responses induced by the high-
cholesterol diet were normalized by L-arginine supplementa-
tion (Figure 1, C).
Endothelial Cell Density
Figure 2 shows the density of CD31 capillary endothelial
cells in the left lateral wall of pigs from all diet groups 4
weeks after initiating VEGF treatment. The cell density was
significantly higher in the normal diet and the L-arginine
groups compared with that in the high-cholesterol-diet
group (95  12 vs 90  15 vs 48.3  10, respectively; P 
.05). Examples of histologic sections are also shown.
Regional Contractility
For differences in the posttreatment versus pretreatment
percentages of segmental shortening in the short axis, al-
though a trend toward increased improvements in the nor-
mal diet (7.0%  2.5%) and the L-arginine (7.9%  3.3%)
groups compared with that in the high-cholesterol group
(1.3%  0.8%) was shown, statistical significance was not
achieved because of variability within the groups (P  .21
by means of 1-way analysis of variance; P .08 for normal
diet vs high-cholesterol diet; P  .09 for L-arginine vs
high-cholesterol diet).
Myocardial Perfusion
The results of isotope-labeled microsphere assays are
depicted in Figure 3. Three weeks after ameroid place-
ment, at the time of VEGF treatment initiation, baseline
circumflex coronary flow was similar among the 3
groups, both at rest (NORM, 0.53  0.05 mL · min1 ·
g1; HICHOL, 0.51  0.07 mL · min1 · g1; HICHOL-
e 2005
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PARG, 0.47  0.03 mL · min1 · g1) and during pacing
(NORM, 0.49  0.06 mL · min1 · g1; HICHOL, 0.49
 0.04 mL · min1 · g1; HICHOL-ARG, 0.45  0.05
mL · min1 · g1). After 4 weeks of VEGF therapy, at the
time of the final procedure, circumflex myocardial blood
flow both at rest and during pacing was significantly
higher in the normal diet group than in its high-choles-
terol counterpart. Respective ratios of blood flow in the
circumflex to the LAD territories in the posttreatment
versus pretreatment settings were 1.18  0.07 (normal
diet) versus 0.95  0.03 (high-cholesterol diet) at rest (P
 .05) and 1.13  0.05 (normal diet) versus 0.74  0.08
(high-cholesterol diet) during pacing (P  .01), thus
Figure 1. Microvascular reactivity studies: percentag
agents after preconstriction with U46619. ADP, Endothe
partially endothelium-dependent vasodilator vascular
endothelium-independent vasodilator. A, Normal diet
diet with L-arginine supplementation.corresponding in increases from baseline perfusion of
The Journal of Thoracic18% and 13% for the normal diet group, respectively, at
rest and during pacing, whereas there were decreases of
5% at rest and 20% during pacing for the high-cholesterol
group. L-Arginine administration resulted in improve-
ments in perfusion that were similar to those observed in
the normal diet group (ratios of 1.13  0.05 at rest and
1.20  0.12 during pacing; not significant vs NORM, P
 .05 vs HICHOL).
Western Blot Analyses
Myocardial VEGF, eNOS, and Akt protein expression
were significantly different among the 3 groups. Densi-
tometry of protein levels in the ischemic and the non-
axation to increasing concentrations of vasodilating
-dependent vasodilator adenosine diphosphate; VEGF,
thelial growth factor; SNP, sodium nitroprusside, an
p. B, High-cholesterol diet group. C, High-cholesterole rel
lium
endo
grouischemic territories is displayed in Figure 4.
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In this study significant coronary microvessel endothelial
dysfunction was induced in a swine model of chronic isch-
emia by means of administration of a cholesterol-rich diet.
This was associated with a markedly decreased functional
response to the angiogenic effects of exogenous VEGF in
comparison with that seen in pigs undergoing the same
VEGF treatment but maintained on a regular chow. Chronic
oral supplementation of L-arginine to pigs receiving the
same high-cholesterol regimen normalized their coronary
microvascular response to endothelium-dependent and
endothelium-independent vasorelaxing agents, which was
Figure 2. Top, Immunohistochemical staining for CD31 (CD31)
and corresponding negative control of an adjacent section (neg-
ative controls) in the left circumflex territory according to diet
regimen 4 weeks after VEGF treatment. Bottom, Bar graph sum-
marizing endothelial cell density results in the corresponding diet
groups. *P < .05.1418 The Journal of Thoracic and Cardiovascular Surgery ● Junassociated with a restored angiogenic response to exoge-
nous VEGF.
Porcine models of hypercholesterolemia-induced endo-
thelial dysfunction have previously been described. Pigs fed
a cholesterol-rich diet for as little as 9 weeks have been
shown to display attenuated endothelium-dependent relax-
ation to serotonin, despite the absence of intimal prolifera-
tive changes,16 and 10 weeks of this diet has also been
associated with reduced vasorelaxation to bradykinin.17 Al-
though pigs from our study clearly showed impaired vasore-
laxation to ADP and VEGF, both endothelium-dependent
Figure 3. Perfusion analyses. Post-VEGF versus pre-
VEGF treatment ratios of circumflex (LCx) versus
LAD blood flows in the different group treatments.
The ratios are presented for both resting and stress
conditions by ventricular pacing at 150 beats/min.
Open column, Rest; filled column, pace. *P < .05.
Figure 4. A, Western blot analysis of VEGF, eNOS, and Akt protein
levels in myocardial tissue harvested from the ischemic and
nonischemic territories in all pigs 4 weeks after VEGF treatment.
Ponceau S optical density was used as a correction factor for
quantification. Relevant statistically significant differences in ex-
pression levels were highlighted, and P values are presented.
Filled column, LAD; open column, left circumflex artery. *P < .05;
**P < .01.e 2005
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Pvasodilators, there also was a significantly decreased re-
sponse to SNP, an endothelium-independent agent. This
suggests a partial contribution from the smooth muscle
cell–mediated vasodilatation to the observed response in our
model, a function that might be directly affected by pro-
gression of the atherosclerotic process in the microcircula-
tion. Although endothelium independent, SNP still ulti-
mately causes vasorelaxation through NO release. The
altered response in the high-cholesterol group could be
explained in part by an accelerated degradation of SNP-
derived NO by the increased superoxide anion production
associated with hypercholesterolemia. Increased oxidative
stress resulting from the induction of xanthine oxidase and
reduced nicotinamide adenine dinucleotide/reduced nicotin-
amide adenine dinucleotide phosphate oxidase and uncou-
pling of eNOS with inactivation from reactive oxygen spe-
cies have been proposed to explain the relationship between
hypercholesterolemia and endothelial dysfunction.18 In our
study the normalization of the microvascular response to
ADP and VEGF resulting from L-arginine administration
was associated with significant increases in levels of VEGF,
Akt, and eNOS. Although the mechanisms that govern the
activation of the signaling pathways leading to Akt and
eNOS expression remain incompletely understood, these
results suggest that modulation of expression of these mol-
ecules plays a role in the endothelial dysfunction that ac-
companies hypercholesterolemia. Asymmetric dimethyl-
arginine, an arginine analog that competes with L-arginine
for eNOS,19 is increased in hypercholesterolemia and can
also contribute to impairment of endothelial function.20
Providing more substrate for eNOS in our HICHOL-ARG
group might have turned this competition mechanism in
favor of NO production because it is known that the com-
petitive inhibition of eNOS by asymmetric dimethylarginine
can be reversed with supplemental L-arginine.21 This find-
ing not only provides another possible mechanism for the
normalization of endothelial function caused by L-arginine
but also supports a substantial association between VEGF
and eNOS in orchestrating the angiogenic process. Two
recent studies in apolipoprotein E–hypercholesterolemic
mice exhibiting attenuated collateral vessel formation in
response to a FGF-2 disk angiogenesis system and hind-
limb ischemia, respectively,22,23 showed that the angiogenic
potential can be fully restored through the oral administra-
tion of L-arginine. Our study brings evidence that hypercho-
lesterolemia-induced myocardial impairment of angiogene-
sis can also be overcome by L-arginine, closing in on the
population of patients with advanced CAD who have thus
far been poorly served by therapeutic angiogenesis. Consid-
ering the critical importance of NO release in the VEGF-
mediated angiogenic response, a role for eNOS and its
precursor Akt in the molecular events involved in the al-
The Journal of Thoracictered angiogenic process associated with endothelial dys-
function is plausible and suggested in these patients.
In similar experimental designs comparing groups of
pigs receiving the same diet regimen, we have previously
shown that hypercholesterolemia-induced endothelial dys-
function significantly impairs both VEGF- and FGF-2–
mediated myocardial angiogenesis.9,24 It is believed that
FGF-2–induced angiogenesis is dependent on Syndecan-4/
protein kinase C  and relatively independent of Src ki-
nases, in contrast to VEGF-induced angiogenesis, which
invariably involves serine phosphorylation–activation of
eNOS and the generation of NO in endothelial cells.25
Although this might result in a considerably different mech-
anistic link between the action of each of these growth
factors and the local availability of NO, likely caused by key
differences in their respective signal transduction pathways,
endothelial dysfunction is the common denominator of
growth factor–mediated angiogenesis inhibition in both of
these studies. The model, however, obviously does not
reproduce the multiple comorbid conditions observed in
patients with CAD and the complex interactions by which
they can impair endothelial function, and this constitutes an
important limitation to our study. In this regard, however, it
is interesting that the beneficial effects observed after L-
arginine administration are independent of modulations in
the cholesterol levels and thus of any effect on the probable
cause of endothelial dysfunction itself.
Taken together, these results suggest a paramount role
for endothelial integrity in the success of protein growth
factor–based therapeutic angiogenesis. This might explain
the discrepancy observed to date between animal and clin-
ical studies testing therapeutic angiogenesis and warrants
the use not only of more appropriate research models dis-
playing some degree of endothelial dysfunction but also of
multimodal therapeutic approaches. To this end, the appar-
ent capacity of eNOS to produce sufficient NO when ade-
quately supplied with L-arginine indicates that the enzyme is
at least partially functional, and combinations of growth
factors with synthetic NO donors, eNOS activators, or an-
tioxidants are other potentially interesting avenues.
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Discussion
Dr Harold L. Lazar (Boston, Mass). Have you considered using
a statin instead of L-arginine? We and others have shown that
pretreatment with statins in a similar model—we used a noncho-
lesterol model—greatly protects and enhances the reaction and
vasodilatation to endothelial function, so that in itself has a pro-
tective effect. Have you considered doing that?
Dr Voisine. This is a very insightful comment, and I thank you for
it. We have indeed considered it, and we currently have groups of pigs
receiving the hypercholesterolemic diet that are administered statins
and that are planned to undergo a similar experimental protocol with
growth factors. Interestingly, the L-arginine supplementation could
overcome the endothelial dysfunction without affecting the choles-
terol levels, which makes our model particularly attractive to study the
combination of statins and growth factors.
Dr Lazar. It is a very interesting observation. But that is
exactly what we saw, that statins, in the model of normal choles-
terol levels, will actually improve endothelial function in the
absence of any effect on endothelial function because, as you
know, pigs by themselves do not make cholesterol. Therefore this
is one of the pleiotrophic effects of statins, which I think would
make it so good for this particular model.
Dr Robert C. Robbins (Stanford, Calif). We also have been
taking our atorvastatin (Lipitor) every morning, so that is good.
How much arginine did you have to give? I did not see it in
your abstract, or you did not mention how much you had to give.
Dr Voisine. We roughly gave 50 mg/kg twice daily.
Dr Robbins. Because, as you probably well know, I am sure
Frank does, there is a cardiologist at Stanford who started a whole
company on arginine bars. But the fact is, you have to give boatloads
of this stuff to get any effect. Did you measure any levels?
Dr Voisine. We tried to measure the levels, and we did not
observe any difference between the different treatment groups. This
might be due to the very rapid turnover of L-arginine. We initially
used a higher dose and had a few cases of aortic thrombi with
hind-limb ischemia. We could not demonstrate a causal relationship
between L-arginine administration and thrombus formation, but be-
cause it only occurred in that treatment group, we decreased the dose
to 50 mg/kg twice daily and did not encounter other adverse events.
Dr Guo-Wei He (Hong Kong, China). VEGF has 2 major
subtypes of receptors, KDR and FLT. I am wondering whether you
have tested which subtype of VEGF receptors, KDR or FLT,
mediates the effect in these microvessels.
Dr Voisine. That is another very interesting point. We used
VEGF165, and we are currently looking at the expression of both
receptors. Unfortunately, it has been very difficult to perform ade-
quate Western blot analyses thus far, and we are now studying the
mRNA expression of both receptors of VEGF by means of Northern
blotting. Our results are preliminary, but hopefully we will have
answers to this question soon.
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